Although no further studies are currently planned with GSK2245035, future development of a TLR7 modulator may be beneficial via an alternative route and or therapeutic indication, such as inhaled route for asthma and intranasal route for immunotherapy adjuvant. This evidence concerns the gene TLR7 and asthma.